Prevalence and Management of Diabetic Nephropathy in Western Countries. - Wikidata - awgldk - TriplyDB

Prevalence and Management of Diabetic Nephropathy in Western Countries.

Prevalence and Management of Diabetic Nephropathy in Western Countries.

http://www.wikidata.org/entity/Q37069905

about

Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus.Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects.Dietary Approaches in the Management of Diabetic Patients with Kidney Disease.GS-E3D, a new pectin lyase-modified red ginseng extract, inhibited diabetes-related renal dysfunction in streptozotocin-induced diabetic rats.Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion.Tubulointerstitial Biomarkers for Diabetic Nephropathy.

P2860

Q33741426-41E58A53-DB07-4ED5-A812-E640C8877045 Q38635763-A1BE5A33-E22F-46A2-9259-306FFFF574DF Q40101494-0B477A91-F07C-40CE-BE05-98932362B81F Q41558335-0F7E3ABF-2925-413F-904A-AD11A1675F38 Q48610499-517D5583-0D66-4EE6-9BBB-E9682463A4EB Q52632440-A999004A-E30E-44DC-B41B-A5E25E356C30

P2860

Prevalence and Management of Diabetic Nephropathy in Western Countries.

http://www.wikidata.org/entity/Q37069905

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Prevalence and Management of Diabetic Nephropathy in Western Countries.

@en

Prevalence and Management of Diabetic Nephropathy in Western Countries.

@nl

type

label

Prevalence and Management of Diabetic Nephropathy in Western Countries.

@en

Prevalence and Management of Diabetic Nephropathy in Western Countries.

@nl

prefLabel

Prevalence and Management of Diabetic Nephropathy in Western Countries.

@en

Prevalence and Management of Diabetic Nephropathy in Western Countries.

@nl

P1433

Q37069905-2C15AC90-8FAB-4041-B020-E3895C0B84B5

P1476

Q37069905-B5F0D950-CFC6-4D95-8E3C-68B642A3CF09

P2093

Q37069905-3321086B-3567-4222-97F8-A6F6CD0E14D5

Q37069905-3EB42528-8A4C-4991-A777-C2B781B58BFA

P2860

Q37069905-02012E0D-E5B4-4570-AD8F-559B21B53659

Q37069905-1249D1CE-4FE7-4DAF-95DF-98C4378EFDF1

Q37069905-177D0D5B-2D92-4D78-9D9E-B9EC0444BAE3

Q37069905-196B46C6-39A4-4010-B60D-46E30893822C

Q37069905-1FF96171-0A39-47E7-A560-6851A7E43FDE

Q37069905-26CFA3ED-ADF9-4A4E-83CB-6048247C9382

Q37069905-2C2A6270-6797-4CED-8CD3-0AA53A410D8A

Q37069905-2D195C19-7178-45B4-A991-AC5ED6AAFAFD

Q37069905-2F78856F-5C57-4E25-A2C5-BCFB711A4F52

Q37069905-3222D711-3A0A-4B75-80B6-8B82D73D306F

P304

Q37069905-B78C47C7-6FC5-4B2E-84FE-D1DF6142E04D

P31

Q37069905-005F8785-E4FE-4CFF-9BBF-82FFC640C5A3

P356

Q37069905-E93B5191-F372-4B63-A622-6C2CF46254D2

P433

Q37069905-ED33F0BD-860C-4E9D-BC3B-6B195F6A8716

P478

Q37069905-7052061C-3E34-419B-A7FA-AB51F153C29F

P577

Q37069905-4145FDDF-6EEF-4165-B96F-C712D0857612

P5875

Q37069905-4BB9E7B2-CD98-44F7-B596-6B23EF0C54F1

P698

Q37069905-9AB4CFBA-2EF7-429C-A360-74F3281DAABD

P932

Q37069905-35798A03-5F1E-4138-A295-0A60377568C5

P356

P1433

Kidney diseases (Basel, Switzerland)

P1476

Prevalence and Management of Diabetic Nephropathy in Western Countries.

@en

P2093

Bancha Satirapoj

http://www.w3.org/2001/XMLSchema#string

Sharon G Adler

http://www.w3.org/2001/XMLSchema#string

P2860

Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Effects of intensive glucose lowering in type 2 diabetes

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

P304

61-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000382028

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277926110

http://www.w3.org/2001/XMLSchema#string

P698

27536666

http://www.w3.org/2001/XMLSchema#string

P932

4934803

http://www.w3.org/2001/XMLSchema#string